ORIC Pharmaceuticals, Inc. (ORIC) Income Statement
ORIC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsORIC revenue and net income
ORIC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ORIC quarterly EPS vs estimates
ORIC Pharmaceuticals beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.40).
ORIC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.2M | $1.1M | $1.0M | $966,000 | $897,000 | $970,000 | $1.0M | $900,000 | $900,000 |
| Gross profit | −$1.2M | −$1.1M | −$1.0M | −$966,000 | −$897,000 | −$970,000 | −$1.0M | −$900,000 | −$900,000 |
| Research & development | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M | $60.8M | $22.8M | $19.0M | $19.1M |
| Sales, general & admin | $33.2M | $28.8M | $26.6M | $25.1M | $22.0M | $13.4M | $5.7M | $3.3M | $3.4M |
| Total operating expenses | $141.8M | $141.8M | $109.7M | $91.8M | $78.9M | $74.2M | $27.6M | $22.4M | $21.6M |
| Operating income | −$143.0M | −$142.9M | −$110.8M | −$91.8M | −$78.9M | −$74.2M | −$28.6M | −$22.4M | −$22.5M |
| Interest income | — | — | — | $2.6M | $141,000 | $306,000 | $1.4M | $775,000 | — |
| Interest expense | — | — | — | $2.6M | $141,000 | $306,000 | $1.7M | $1.0M | $0 |
| Income before taxes | −$129.5M | −$127.8M | −$100.7M | −$89.1M | −$78.7M | −$73.7M | −$26.9M | −$21.4M | −$22.0M |
| Income taxes | — | — | — | $2.4M | −$1.0M | $23.6M | −$1.4M | −$1.0M | — |
| Net income | −$129.5M | −$127.8M | −$100.7M | −$89.1M | −$77.7M | −$73.7M | −$26.9M | −$21.4M | −$22.0M |
| EBITDA | −$128.2M | −$126.7M | −$99.7M | −$85.8M | −$78.0M | −$48.4M | −$25.9M | −$20.5M | −$21.1M |
| EPS (diluted) | −$1.52 | −$1.82 | −$1.96 | −$2.25 | −$2.07 | −$2.61 | −$0.08 | −$10.68 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.1M | $0 | $0 | $0 | $1.5M | $0 |
| Cost of revenue | $264,000 | — | $320,000 | — | $310,000 | $302,000 | $304,000 | $270,000 | $272,000 | $261,000 | $263,000 | $257,000 |
| Gross profit | −$264,000 | — | −$320,000 | — | −$310,000 | −$302,000 | −$304,000 | −$270,000 | −$272,000 | −$261,000 | −$263,000 | −$257,000 |
| Research & development | $36.3M | $31.4M | $25.9M | $28.8M | $30.5M | $24.6M | $32.0M | $31.2M | $28.9M | $22.0M | $24.5M | $22.4M |
| Sales, general & admin | $9.0M | $8.2M | $8.7M | $7.9M | $8.5M | $8.1M | $7.6M | $7.1M | $7.1M | $7.3M | $7.2M | $6.3M |
| Total operating expenses | $45.0M | $39.6M | $34.2M | $36.7M | $39.1M | $32.7M | $39.3M | $38.3M | $36.0M | $28.7M | $31.2M | $28.7M |
| Operating income | −$45.3M | −$39.6M | −$34.6M | −$36.7M | −$39.1M | −$32.7M | −$39.6M | −$38.3M | −$36.0M | −$29.0M | −$31.4M | −$28.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.0M | — |
| Income before taxes | −$41.5M | −$35.8M | −$30.5M | −$32.6M | −$36.4M | −$30.0M | −$36.3M | −$34.6M | −$32.0M | −$25.0M | −$28.3M | −$25.5M |
| Income taxes | — | — | — | — | — | — | — | — | −$272,000 | $217,724 | $2.2M | −$257,000 |
| Net income | −$41.5M | −$35.8M | −$30.5M | −$32.6M | −$36.4M | −$30.0M | −$36.3M | −$34.6M | −$32.0M | −$25.0M | −$28.3M | −$25.5M |
| EBITDA | −$45.0M | −$35.5M | −$30.2M | −$32.3M | −$36.0M | −$29.7M | −$36.0M | −$34.3M | −$31.7M | −$24.8M | −$28.1M | −$25.2M |
| EPS (diluted) | −$0.38 | −$0.34 | −$0.30 | −$0.33 | −$0.47 | −$0.42 | −$0.51 | −$0.49 | −$0.45 | −$0.37 | −$0.49 | −$0.44 |
| Gross margin | — | — | — | — | — | — | −28.5% | — | — | — | −17.1% | — |
| Operating margin | — | — | — | — | — | — | −3,712.0% | — | — | — | −2,043.4% | — |
| Net margin | — | — | — | — | — | — | −3,405.9% | — | — | — | −1,842.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ORIC's financial statements (latest annual report filed February 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ORIC financial results
ORIC Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $129.5 million. Diluted earnings per share came to −$1.52.
See the ORIC stock overview for the latest quote and news, or the ORIC chart for price history and technical indicators.
ORIC income statement FAQ
Does ORIC Pharmaceuticals have revenue?
ORIC Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is ORIC Pharmaceuticals profitable?
No. ORIC Pharmaceuticals reported a net loss of $129.5 million in fiscal 2025.
How much does ORIC Pharmaceuticals spend on research and development?
ORIC Pharmaceuticals spent $109.8 million on research and development in fiscal 2025.
What are ORIC Pharmaceuticals's earnings per share?
ORIC Pharmaceuticals earned $-1.52 per diluted share in fiscal 2025, compared with $-1.82 a year earlier.
When will ORIC Pharmaceuticals report its next earnings?
ORIC Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does ORIC Pharmaceuticals's fiscal year end?
ORIC Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 23, 2026.